A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970
Status:
Completed
Trial end date:
2021-03-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of GLPG3970 in
healthy volunteers after single oral administrations of GLPG3970 (SAD), compared to placebo
(part 1 and 1bis) and after multiple (for 14 days) oral administrations of GLPG3970 (MAD),
compared to placebo (part 2). The effect of food (FE) (high-fat, high calorie) on the
pharmacokinetics of GLPG3970 and the relative bioavailability (rBA) of an oral solution
versus a solid formulation will be assessed (part 3 and 3bis). Part 4 of the study is to
evaluate the safety and tolerability of GLPG3970 in subjects with moderate to severe
psoriasis when administered daily for 6 weeks.